Microba Life Sciences, launched at TRI in 2018, pioneered advanced DNA analysis technology known as metagenomics for comprehensive gut microbiome analysis, illuminating the complex relationships between microorganisms and health to advance personalised medicine.
Under the guidance of TRI ambassador Prof Ian Frazer AC and a team of microbiome experts, Microba developed the world’s first accredited diagnostic test capable of detecting 175 gut pathogens in a single exam. This breakthrough attracted international healthcare partners for the global rollout of at-home gut health testing.
Following a successful A$30m IPO in 2022, Microba continues to expand its gut analysis services while developing new treatments for autoimmune conditions. Research with the Australian Department of Defence further underscores the technology’s broader potential.
US$1.4tn
global gut health market
175
gut pathogens detected in one test
A$30m
raised in 2022 IPO
